Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Department of Thoracic Surgery, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Oncol Res Treat. 2021;44(11):590-601. doi: 10.1159/000519454. Epub 2021 Sep 23.
Pulmonary sarcomatoid carcinoma (PSC) is a very rare subtype of non-small-cell lung cancer (NSCLC). It is frequently diagnosed in the advanced stage and is resistant to conventional chemotherapeutics. Due to the unique nature and rarity, we evaluated the epidemiological, clinicopathological, and survival data of PSC patients treated at our centre.
We retrospectively collected demographic and clinical data of 67 PSC patients from a single tertiary referral hospital, between the 2000 and 2018. Univariate and multivariate analyses were performed to determine the risk factors affecting survival.
The median age was 61 years, and the percentage of male was 74.6%. Most of the patients had a smoking history (76.9%). The most common PSC subtype was pleomorphic carcinoma (46.3%). The median overall survival (OS) was 55.4 months, and the 5-year OS rate was 47.5%. Advanced stage, T4 tumour, and positive lymph node involvement were associated with poor OS (p < 0.05). The patients with negative epithelial markers had poorer prognosis (p = 0.027) and had more frequently stage IV disease (p = 0.016). Surgical treatment and stage IV disease were determined to be independent prognostic factors.
PSC is an extremely rare and aggressive variant of NSCLC. Positive epithelial markers may have favourable prognostic significance in PSC. Resection of the tumour with a negative surgical margin is crucial for better survival. The prognosis of the disease is very poor in the metastatic stage.
肺肉瘤样癌（PSC）是一种非常罕见的非小细胞肺癌（NSCLC）亚型。它通常在晚期被诊断，并且对常规化疗药物具有耐药性。由于其独特的性质和罕见性，我们评估了在我们中心治疗的 PSC 患者的流行病学、临床病理和生存数据。
我们回顾性地收集了 2000 年至 2018 年间一家三级转诊医院的 67 名 PSC 患者的人口统计学和临床数据。进行单因素和多因素分析以确定影响生存的危险因素。
中位年龄为 61 岁，男性比例为 74.6%。大多数患者有吸烟史（76.9%）。最常见的 PSC 亚型是多形性癌（46.3%）。中位总生存期（OS）为 55.4 个月，5 年 OS 率为 47.5%。晚期、T4 肿瘤和阳性淋巴结受累与较差的 OS 相关（p < 0.05）。上皮标志物阴性的患者预后较差（p = 0.027），且更常处于 IV 期疾病（p = 0.016）。手术治疗和 IV 期疾病被确定为独立的预后因素。
PSC 是一种非常罕见且侵袭性的 NSCLC 变体。上皮标志物阳性可能对 PSC 具有有利的预后意义。切除有阴性手术切缘的肿瘤对于更好的生存至关重要。在转移阶段，疾病的预后非常差。
